Clinical trial
Iressa in Poor Performance Status Patients With Previously Untreated Advanced…
NCT00193336 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193336 |
|---|---|
| Title | Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Single Agent ZD1839 (Iressa) in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | ZD1839 |
| Enrollment | 60 |
| Start date | Mar 1, 2003 |
| Primary completion | Mar 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: